頁籤選單縮合
題名 | Drotrecogin-α使用加護病房嚴重敗血症患者療效評估=Drug Utilization Evaluation of Drotrecogin-α in Adult Critical Patients with Severe Sepsis |
---|---|
作者 | 黃美嫆; 黃金鈴; 汪忠炫; 黃炳文; 鄭恩宗; | 書刊名 | 藥學雜誌 |
卷期 | 27:3=108 2011.09[民100.09] |
頁次 | 頁93-99 |
分類號 | 418.2325 |
關鍵詞 | 藥物使用評估; 活化蛋白質C; 嚴重敗血症; Drotrecogin-α; |
語文 | 中文(Chinese) |
中文摘要 | 嚴重敗血症常是造成重症病人死亡原因之一, drotrecogin-α雖可降低嚴重敗血症的死亡率,但價錢昂貴及其出血的副作用,限制了它的使用。本研究採回溯性研究收集 2006年7月至 2009年7月,共收集 20位加護病房患者進行分析評估,探討經 drotrecogin-α藥物治療後,患者存活率及出血副作用做為本院 drotrecogin-α藥品使用依據。結果顯示治療後死亡率 (50%),存活率 (50%)。分成死亡及存活患者兩組比較,患者的 Plasma D-Dimer (p=0.018),multiple organic failure (p=0.021)等具有統計義意。重症專科及原專科醫師 (close system n=14 vs. open system n=6)比較,患者死亡率分別是 28.6%及100%。本研究經由分析 drotrecogin-α病患的特性與存活率關係,出血的副作用及藥費相關資料回饋給臨床醫生,提供本院 drotrecogin-α使用標準,以提高敗血症病患的生存率及預後為目標。 |
英文摘要 | Severe sepsis is one of the death related causes in critical ill patient. Drotrecogin-α has been indicated to increase the survival rate in high risk adult with severe sepsis. The high cost and hemorrhage side effect limited its utilization. We conducted a retrospective study and evaluate its efficacy in critical patients. The data was collected from July 2006 to July 2009. We evaluate the survival and mortality rate after treatment with drotrecogin-α. Utilization of drotrecogin-α in critically ill patient with high risk severe sepsis, mortality rate 50% versus survival rate 50% respectively. There were significant p-value showed in plasma D-dimer (p-value 0.018) and multiple organic failures (p-value 0.021). We also compared the physician prescription and found that utilization of drotrecogin-α by open system intensive care 100% mortality rate versus 28.6% by close system intensive care.In this regard, it should be noted to the intensive care specialist that the utilization of drotrecogin-α must be more considerable to approach a more successful outcome to save one life and notice it is side effect. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。